Investing.com - Royalty Pharma reported on Tuesday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Royalty Pharma announced earnings per share of $0.24 on revenue of $573M. Analysts polled by Investing.com anticipated EPS of $0.71 on revenue of $584.92M.
Royalty Pharma shares are down 35% from the beginning of the year and are trading at $42.48 , down-from-52-week-high.
Royalty Pharma shares gained 0.27% in intra-day trade the report.
Royalty Pharma follows other major Healthcare sector earnings this month
Royalty Pharma's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar